List of programme's course units, number of exams (i.e. how many times the exam was taken in a year) and average marks
The data refer to last year. A course unit may include modules, subgroups, integrated exams. Proficiency tests are not included in the list.
| Course unit | Number of times exam was taken | Average mark |
|---|---|---|
| MICROBIOLOGY AND VACCINES | 24 | 28 |
| BIOMOLECULAR SIMULATIONS FOR DRUG DESIGN | 41 | 28 |
| NANOBIOTECHNOLOGY | 1 | 28 |
| INDUSTRIAL PROCESSES FOR RECOMBINANT DRUGS | 43 | 27 |
| LEGAL AND ECONOMIC ASPECTS OF PHARMACEUTICAL BIOTECHNOLOGY (I.C.) | 37 | 29 |
| STRUCTURAL BASES OF MOLECULAR INTERACTIONS | 1 | 30 |
| MOLECULAR MECHANISMS OF DISEASES | 3 | 26 |
| GENOMICS OF DISEASES (I.C.) | 39 | 28 |
| BIOSENSORS | 44 | 28 |
| CHEMICAL AND GENOMICS-BASED STRATEGIES IN THE DISCOVERY OF NOVEL DRUG TARGETS | 7 | 30 |
| NEUROBIOTECHNOLOGY | 30 | 30 |
| ADVANCED IMMUNOLOGY | 14 | 28 |
| INDUSTRIAL SCALE UP OF BIOPROCESSES | 1 | 28 |
| MOLECULAR INTERACTION NETWORKS (I.C.) | 1 | 20 |
| ADVANCED TECHNIQUES FOR THE STUDY OF METABOLISM IN VIVO | 30 | 28 |
| BIOSENSORS | 1 | 30 |
| STEM CELLS AND 3D ORGANOID SYSTEMS | 40 | 30 |
| APPLIED GENOMICS | 5 | 26 |
| ANTIVIRAL AND ANTIMICROBIAL STRATEGIES | 5 | 26 |
| ANALYTICAL CHALLENGES IN THE BIOPHARMACEUTICAL FIELD | 3 | 24 |
| SAFETY AND QUALITY OF BIOPHARMACEUTICAL PRODUCTS (I.C.) | 41 | 28 |
| SAFETY PHARMACOLOGY AND TOXICOLOGY OF BIOPHARMACEUTICALS | 2 | 28 |
| TECHNOLOGICAL INNOVATION AND PRODUCT DEVELOPMENT | 2 | 29 |
| DOWNSTREAM PROCESSES OF BIOLOGICAL MOLECULES | 3 | 25 |
| EUROPEAN AND INTERNATIONAL REGULATION AND PATENTS | 1 | 28 |
| NANOBIOTECHNOLOGY (I.C.) | 38 | 24 |
| PHARMACOTHERAPY OF BIOLOGICAL DRUGS | 44 | 28 |
| MOLECULAR INTERACTION NETWORKS (I.C.) | 44 | 26 |
| INDUSTRIAL BIOTECHNOLOGICAL APPLICATIONS (I.C.) | 1 | 18 |
| INDUSTRIAL BIOTECHNOLOGICAL APPLICATIONS (I.C.) | 36 | 28 |
